Show simple item record

dc.contributor.authorBlackhall, Fiona Hen
dc.contributor.authorPeters, Sen
dc.contributor.authorBubendorf, Len
dc.contributor.authorDafni, Uen
dc.contributor.authorKerr, Ken
dc.contributor.authorHager, Hen
dc.contributor.authorSoltermann, Aen
dc.contributor.authorO'Byrne, Ken
dc.contributor.authorDooms, Cen
dc.contributor.authorSejda, Aen
dc.contributor.authorHernández-Losa, Jen
dc.contributor.authorMarchetti, Aen
dc.contributor.authorSavic, Sen
dc.contributor.authorTan, Qen
dc.contributor.authorThunnissen, Een
dc.contributor.authorSpeel, Een
dc.contributor.authorCheney, Ren
dc.contributor.authorNonaka, Daisukeen
dc.contributor.authorde Jong, Jen
dc.contributor.authorMartorell, Men
dc.contributor.authorLetovanec, Ien
dc.contributor.authorRosell, Ren
dc.contributor.authorStahel, Ren
dc.date.accessioned2014-08-05T14:04:36Z
dc.date.available2014-08-05T14:04:36Z
dc.date.issued2014-07-28
dc.identifier.citationPrevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. 2014: J Clin Oncolen
dc.identifier.issn1527-7755
dc.identifier.pmid25071109
dc.identifier.doi10.1200/JCO.2013.54.5921
dc.identifier.urihttp://hdl.handle.net/10541/324239
dc.description.abstractThe prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non-small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen
dc.titlePrevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project.en
dc.typeArticleen
dc.contributor.departmentFiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchesteren
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractThe prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non-small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population.


This item appears in the following Collection(s)

Show simple item record